Cargando…

Use of Convalescent Plasma in COVID-19 Patients: Guayaquil, Ecuador Experience.

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Hubei province, China in December 2019; pneumonia caused by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19).(1) Several antiviral and anti-inflammatory therapies have been proposed such as hydroxych...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plaza, Carlos, Sabando, Brener, Loor Morán, Yaira, Posligua, Maria Alejandra, Layedra, Luis, Oliveros-Alvear, Jorge William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	401.Basic Science and Clinical Practice in Blood Transfusion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330285/ http://dx.doi.org/10.1182/blood-2020-142664

Ejemplares similares

Oxygenation and Inflammatory Markers after Early Covid-19 Convalescent Plasma: A Comparison of Survivors and Non-Survivors
por: Baez Sosa, Valentina, et al.
Publicado: (2021)

Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience
por: Browning, Sabrina L., et al.
Publicado: (2020)

Leveraging the Power of a Healthcare System to Fulfill the COVID Convalescent Plasma Needs Early in the COVID-19 Pandemic
por: Baez Sosa, Valentina, et al.
Publicado: (2020)

Antibody Response Against Sars-Cov-2 in Convalescent Plasma Donors: Preliminary Results from a Single Center in Midwest Brazil
por: Roberti, Maria do Rosario Ferraz, et al.
Publicado: (2020)

The Challenge of Recruiting Convalescent Plasma Donors during the COVID-19 Pandemic: Preliminary Results from a Single Center in Midwest Brazil
por: Roberti, Maria do Rosario Ferraz, et al.
Publicado: (2020)

A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients
por: Al Hashmi, Hani, et al.
Publicado: (2020)

Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study
por: Khanna, Nina, et al.
Publicado: (2020)

COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients
por: Ibrahim, Moayed, et al.
Publicado: (2020)

Phase I and Preliminary Results of a Phase II Study (TERAPLASCoV2) of Convalescent Plasma in Patients with Severe and Life-Threatening Pneumonia Caused By Sars-Cov-2
por: Pérez-Jacobo, Fernando, et al.
Publicado: (2020)

Impact of Blood Group Type on Severity of Disease in COVID-19 Patients
por: Rao, Shivani, et al.
Publicado: (2020)

Correlation between ABO Blood Groups and Disease Severity and Mortality in Hospitalized COVID-19 Patients
por: Ramo, Aula, et al.
Publicado: (2020)

Hemorrhage Is a Major Cause of Blood Transfusion in COVID-19 Patients
por: Sanz, Cristina, et al.
Publicado: (2020)

ABO/Rh Blood Group and COVID-19 Infection Severity
por: Hermel, David J, et al.
Publicado: (2020)

Caring for Patients with Sickle Cell Disease during a Pandemic: Continuing to Provide Automated Red Blood Cell Exchange Transfusions in Difficult Times
por: Godby, Richard Curtis, et al.
Publicado: (2020)

COVID-19 Vaccination Motivation and Hesitancy in Heart Transplant Recipients During a Global Health Crisis
por: Mohney, K.L., et al.
Publicado: (2022)

Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)
por: Bajpai, Meenu, et al.
Publicado: (2022)

Convalescent plasma treatment of critically ill intensive care COVID‐19 patients
por: Lindemann, Monika, et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment
por: Bagri, Anil, et al.
Publicado: (2022)

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone
por: Tedder, Richard S., et al.
Publicado: (2018)

Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
por: Refaai, Majed A., et al.
Publicado: (2015)

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2014)

Further Observations on the Results of Blood Transfusion in War Surgery
Publicado: (1918)

A Simple and Rapid Method for the Selection of Suitable Donors for Transfusion by the Determination of Blood Groups
Publicado: (1918)

Transfusion with Tested Bloods
Publicado: (1918)

Reticulocytes in donor blood units enhance red blood cell alloimmunization
por: Thomas, Tiffany A., et al.
Publicado: (2023)

Inhibition of GPIb-α-mediated apoptosis signaling enables cold storage of platelets
por: Marini, Irene, et al.
Publicado: (2023)

Use of convalescent plasma in hospitalized patients with COVID-19: case series
por: Hegerova, Livia, et al.
Publicado: (2020)

Racial differences in red blood cell transfusion in hospitalized patients with anemia
por: Prochaska, Micah, et al.
Publicado: (2022)

How should we use convalescent plasma therapies for the management of COVID-19?
por: Wood, Erica M., et al.
Publicado: (2021)

Outdoor thermal comfort in public space in warm-humid Guayaquil, Ecuador
por: Johansson, Erik, et al.
Publicado: (2017)

Salaried Workers’ Self-Perceived Health and Psychosocial Risk in Guayaquil, Ecuador
por: Gómez-García, Antonio Ramón, et al.
Publicado: (2020)

Teleconsultation Apps in the COVID-19 Pandemic: The Case of Guayaquil City, Ecuador
Publicado: (2021)

PB1734: SURVIVAL OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN ECUADOR. AN ANALYSIS OF THE REAL WORLD
por: Sabando, Brenner, et al.
Publicado: (2023)

Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England
por: Hough, Rachael, et al.
Publicado: (2017)

MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
por: Brown, Sarah, et al.
Publicado: (2021)

Cost implications of implementation of pathogen-inactivated platelets
por: McCullough, Jeffrey, et al.
Publicado: (2015)

Pediatric blood transfusion practices at a regional referral hospital in Kenya
por: Nabwera, Helen M., et al.
Publicado: (2016)

The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions
por: Netelenbos, Tanja, et al.
Publicado: (2018)

Phased implementation of pathogen‐reduced platelets in a health system facilitates increased manufacturing at the blood center
por: Allen, Elizabeth S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d3uu8i02j14o8pp3r2vgi28em0